Literature DB >> 22901216

Prognostic role of microRNA-21 in non-small cell lung cancer: a meta-analysis.

Xue-Lei Ma1, Lei Liu, Xiao-Xiao Liu, Yun Li, Lei Deng, Zhi-Lan Xiao, Yan-Tong Liu, Hua-Shan Shi, Yu-quan Wei.   

Abstract

INTRODUCTION: Many studies have reported that microRNA-21 (miR-21) mihght predict the survival outcome in non-small cell lung cancers (NSCLCs) but the opposite opinion has also been expressed. The aim of this study was to summarize the evidence for a prognostic role of miR-21.
MATERIALS AND METHODS: All the eligible studies was searched by Medline and EMBASE and patients' clinical characteristics and survival outcome were extracted. Then a meta-analysis was performed to clarify the prognostic role of the miR-21 expression in different subgroups.
RESULTS: A total of 8 eligible articles were yielded covering survival outcomes or clinical characteristics. The combined hazard ratio (HR) and 95% confidence interval (95% CI) for overall survival (OS) was 2.19 [0.76, 6.30], while the combined HR (95% CI) of Asian group for OS had a significant result, 5.49 [2.46, 12.27]. The combined HR (95% CI) for recurrence free survival or disease free survival (RFS/DFS) was 2.31 [1.52, 3.49]. Odds ratios (ORs) showed that the miR-21 expression was associated with lymph node status and histological type.
CONCLUSION: miR-21 expression could predict the prognostic outcome of NSCLC in Asians, despite some deficiencies in the study data.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22901216     DOI: 10.7314/apjcp.2012.13.5.2329

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  19 in total

Review 1.  Prognostic and clinicopathological significance of microRNA-21 overexpression in breast cancer: a meta-analysis.

Authors:  Fei Pan; Hui Mao; Ling Deng; Guangchao Li; Peiliang Geng
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 2.  MicroRNA-21: A promising biomarker for the prognosis and diagnosis of non-small cell lung cancer.

Authors:  Wen Zheng; Juanjuan Zhao; Yijing Tao; Mengmeng Guo; Zhou Ya; Chao Chen; Nalin Qin; Jing Zheng; Junmin Luo; Lin Xu
Journal:  Oncol Lett       Date:  2018-06-15       Impact factor: 2.967

3.  Emerging role of microRNA-21 in cancer.

Authors:  Yin-Hsun Feng; Chao-Jung Tsao
Journal:  Biomed Rep       Date:  2016-08-26

Review 4.  MicroRNAs as diagnostic and prognostic biomarkers in colorectal cancer.

Authors:  Rui Yi; Yao Li; Fei-Liang Wang; Gang Miao; Ruo-Mei Qi; Yan-Yang Zhao
Journal:  World J Gastrointest Oncol       Date:  2016-04-15

5.  Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in colorectal cancer.

Authors:  Peng Chen; Qiulei Xi; Qiang Wang; Pei Wei
Journal:  Med Oncol       Date:  2014-09-13       Impact factor: 3.064

6.  Serum MicroRNA Signature Predicts Response to High-Dose Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer.

Authors:  Yilun Sun; Peter G Hawkins; Nan Bi; Robert T Dess; Muneesh Tewari; Jason W D Hearn; James A Hayman; Gregory P Kalemkerian; Theodore S Lawrence; Randall K Ten Haken; Martha M Matuszak; Feng-Ming Kong; Shruti Jolly; Matthew J Schipper
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-09-04       Impact factor: 7.038

7.  Prediction of poor prognosis in breast cancer patients based on microRNA-21 expression: a meta-analysis.

Authors:  Yanyan Wang; Yujie Zhang; Chi Pan; Feixia Ma; Suzhan Zhang
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

Review 8.  Prognostic role of microRNA-21 in gastric cancer: a meta-analysis.

Authors:  Zhenqiang Wang; Qiang Cai; Zhaoyan Jiang; Bingya Liu; Zhenggang Zhu; Chen Li
Journal:  Med Sci Monit       Date:  2014-09-18

9.  Modulation of NF-κB/miR-21/PTEN pathway sensitizes non-small cell lung cancer to cisplatin.

Authors:  Zhenhua Yang; Surong Fang; Yicheng Di; Weiwei Ying; Yan Tan; Wei Gu
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

10.  Prognostic role of microRNA-21 in colorectal cancer: a meta-analysis.

Authors:  Xiaochun Xia; Baixia Yang; Xiaogang Zhai; Xiangyang Liu; Kang Shen; Zhijun Wu; Jing Cai
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.